Germany-based immatics biotechnologies has completed patient recruitment for its Phase III trial evaluating renal cell carcinoma (RCC) vaccine IMA901.

The study is expected to randomise approximately 345 patients with metastatic and/or locally advanced RCC across 10 countries in the US and Europe.

immatics CMO Dr Carsten Reinhardt said the rate of patient recruitment signifies the level of interest in the novel cancer vaccine for the treatment of renal cell carcinoma.

"IMA901, which contains multiple highly relevant tumor peptides, has already indicated the potential to extend patient survival and we look forward to this being confirmed in this pivotal trial," Reinhardt said.

The Phase III IMPRINT trial will evaluate the overall survival benefit of IMA901 in combination with sunitinib, in comparison to sunitinib alone.

Immune response to the peptides contained in IMA901, progression-free survival, safety and tolerability are the secondary endpoints.

Interim overall survival results of the study are expected in the first half of 2014.

Immatics CEO Paul Higham said IMA901 has been designed to redirect the immune system to make it recognise and control tumours.

"We believe that our vaccines could deliver a step-change in the treatment of cancer patients, allowing them to live longer with their cancer while maintaining their quality of life," Higham said.

The US Food and Drug Administration (FDA) has granted orphan drug status to IMA901 for the treatment of renal cell carcinoma in HLA-A*02 positive patients.

Image: Renal cell carcinoma. Photo: Courtesy of Ed Uthman.